http://www.pennystockdetectives.

com/dividend-penny-stocks/great-stock-with-excellentmomentum-declares-special-1-00-dividend

Great Stock with Excellent Momentum Declares Special $1.00 Dividend

Dog may be mans best friend, but it can also be an investors best friend, too. Pets are big business. According to the Federal Trade Commission, 60% of U.S. households owned a pet in 2011. Of the $50.0 billion spent on pets last year, nearly $7.0 billion was spent on pet medications. (Source: Federal Trade Commission, Pet Medications Workshop, last accessed December 4, 2012.) Between 2003 and 2007, the pet medications market grew at an annual rate of 12.5%. Between 2008 and 2012, the market is projected to maintain its double-digital annual growth rate at 11.6%. (Source: DoubleDigit Growth Predicted for Pet Medications, Pet Product News International, 2012; last accessed December 4, 2012.) Some of the prime reasons behind the growth include an aging pet population and an increasing number of overweight pets. Conditions with excessive weight issues include osteoarthritis, cardiac disease, respiratory conditions, dermatological issues, and compromised immune function. Billing itself as Americans largest pet pharmacy, PetMed Express, Inc. (NASDAQ/PETS) sells prescription and non-prescription pet medications, health products, and supplies for cats and dogs in the United States. The company purchases its products at wholesale prices, and ships directly to customers. Non-prescription medicines, such as flea and tick medications, and health and nutritional supplements, account for the majority of PetMeds total sales. The company makes the majority of its sales via its web site. The company has a market cap of $222.3 million, a forward price-to-earnings ratio of 14.64, $62.4 million in cash, and no long-term debt, and provides an annual dividend payment of 5.2%. On October 22, PetMed announced that second-quarter revenue was essentially flat year-over-year at $58.1 million, versus $58.2 million for the quarter ended September 30, 2011. Net income was $4.0 million, or $0.20 per share, compared to net income of $3.9 million, or $0.19 per share, for the quarter ended September 30, 2011. (Source: PetMed Express press release, PETMED EXPRESS D/B/A 1-800PETMEDS ANNOUNCES ITS SECOND FISCAL QUARTER FINANCIAL RESULTS OCTOBER 2012, October 22, 2012.) On October 29, PetMed declared a quarterly dividend payment of $0.15 per share on its common stock. The company intends to continue with regular quarterly dividend payments; however, future dividend payments will be subject to a determination by the Board of Directors each quarter. (Source: PetMed Express press release, PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES ITS QUARTERLY DIVIDEND, October 29, 2012.) On December 3, PetMed announced a special dividend payment of $1.00 per share. The dividend payment will be payable on December 24, 2012, to shareholders of record at the close of business on December 14, 2012. (Source: PetMed Express press release, PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES A SPECIAL DIVIDEND, December 3, 2012.)

Chart courtesy of www.StockCharts.com PetMeds stock has had a volatile year. After a bullish start, the companys share price dropped in early May on weaker fourth-quarter net income. After rebounding slightly, the companys share price fell further on weaker-than-expected first-quarter results. Since August however, the companys share price has been trending steadily higher, and recently broke through a resistance level near $11.50. While PetMeds second-quarter earnings and revenue results were essentially flat quarter-over-quarter, the company did repurchase 397,000 shares of common stock for $3.9 million, at an average share price of $9.74. Looking to the future, the company expects to focus its efforts on advertising efficiency and shifting sales to higher margin items, including generics, while continuing to expand its product offerings. We Told You So On Friday, October 9, financial analyst Mitchell Clark introduced you to ACADIA Pharmaceuticals Inc. (NASDAQ/ACAD) when it was trading at $2.63. Clark noted that Acadias share price had been climbing steadily higher since the beginning of September, after simply announcing it had completed its Phase III trial for its Parkinsons treatment he real good news for Acadia shareholders came on Tuesday, November 27, when the company announced successful results for the Phase III trial of its pimavanserin drug. The compound met the primary endpoint by demonstrating highly significant antipsychotic efficacy. The successful Phase III results helped lift Acadias share price to a new 52-week high of $6.54, for a shortterm gain of 148.6%.